Background: Few studies have reported the burden of generalized pustular psoriasis (GPP), a severe and potentially life-threatening skin disease, especially at a national level. Objectives: The aim of this study is to estimate the nationwide burden of GPP in China and make a systemic review of the published data. Methods: We conducted a population-based study using Urban Basic Medical Insurance in China from 2012 to 2016. GPP cases were identified by primary diagnoses including the international classification of Diseases codes (ICD-10: L40.1 and ICD-9: 694.3). A systematic review was conducted using relevant databases up to January 2022. Results: The crude prevalence and incidence of GPP in 2016 were 1.403 (95% confidence interval [CI]: 1.115–1.691) and 0.629 (95% CI: 0.483–0.775) per 100,000 person-years, respectively. The rates were higher in males than in females for both prevalence (1.429 vs. 1.135) and incidence (0.635 vs. 0.520). The prevalence and incidence showed a bimodal age distribution, with the first peak occurring in the 0- to 3-year age-group and the second peak occurring in the 30- to 39-year age-group. The per capita total cost per year for 1 patient with GPP was 609.26 (± 45.77) US dollars. Seven studies were identified in a systematic review, according to which the prevalence (per 100,000) of GPP tended to be higher in Asian countries (0.746–8.178 in Japan and 12.230 in Korea) than in France (0.176), Sweden (6.25), and Brazil (0.7). Conclusions: This is the largest study concerning the disease burden of GPP, and in this study, the prevalence seemed to be higher in Asia. Although the direct economic burden of GPP did not seem high during the study period, the future usage of biologics and the humanistic burden should also be considered for policy-related decision-making.

Keywords:
Generalized pustular psoriasis, Systematic review, Prevalence, Incidence, Cost, Medical insurance data
1.
Sampogna F, Tabolli S, Söderfeldt B, Axtelius B, Aparo U, Abeni D, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154(5):844–9.
2.
Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100(3):adv00034.
3.
Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067–77.
4.
Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br J Dermatol. 1971;85(5):407–11.
5.
Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16(6):669–73.
6.
Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676–84.
7.
Jin H, Cho HH, Kim WJ, Mun JH, Song M, Kim HS, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015;42(7):674–8.
8.
Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch Dermatol. 1991;127(9):1339–45.
9.
Miyachi H, Konishi T, Kumazawa R, Matsui H, Shimizu S, Fushimi K, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266–74.
10.
Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173–81.
11.
Hamilton MP, Ntais D, Griffiths CE, Davies LM; Identification and Management of Psoriasis-Associated ComorbidiTy IMPACT Team. Psoriasis treatment and management-a systematic review of full economic evaluations. Br J Dermatol. 2015;172(3):574–83.
12.
Li H, Liao D, Meng S, Liu J, Li S, Ni S, et al. Novel IL36RN mutation identified in pediatric-onset generalized pustular psoriasis causes IL36 antagonist degradation. J Clin Immunol. 2021;41(3):701–4.
13.
Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–9.
14.
Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global burden of disease study 2017. J Am Acad Dermatol. 2021;84(1):46–52.
15.
Ohkawara A, Yasuda H, Kobayashi H, Inaba Y, Ogawa H, Hashimoto I, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76(1):68–71.
16.
Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean national health insurance database. Ann Dermatol. 2017;29(6):761–7.
17.
Hanna ML, Singer D, Valdecantos WC. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States. Curr Med Res Opin. 2021;37(5):735–42.
18.
Xu L, Chen L, Wang S, Feng J, Liu L, Liu G, et al. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020;91(5):520–5.
19.
Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, et al. Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study. PLoS Med. 2020;17(8):e1003180.
20.
Tian Y, Liu H, Wu Y, Si Y, Song J, Cao Y, et al. Association between ambient fine particulate pollution and hospital admissions for cause specific cardiovascular disease: time series study in 184 major Chinese cities. BMJ. 2019;367:l6572.
21.
http://www.scio.gov.cn/ztk/dtzt/36048/37159/37165/Document/1565088/1565088.htm.
22.
Zhao B. China clinical dermatology. Jiangsu: Jiangsu Science and Technology Press; 2010. p. 1014.
23.
Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974–8.
24.
Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–70.
25.
Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.
26.
Duarte GV, Esteves de Carvalho AV, Romiti R, Gaspar A, Gomes de Melo T, Soares CP, et al. Generalized pustular psoriasis in Brazil: a public claims database study. JAAD Int. 2022;6:61–7.
27.
Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239–52.
28.
Wang G, Gao TW, Liu YF. Clinical analysis of 76 cases of pustular psoriasis. J Clin Dermatol. 2004;33(12):717–20.
29.
Noe MH, Wan MT, Mostaghimi A, Gelfand JM; Pustular Psoriasis in the US Research Group; Armstrong AW, Agnihothri R, et al. Evaluation of a case series of patients with generalized pustular psoriasis in the United States. JAMA Dermatol. 2022;158(1):73–8.
30.
Cowen EW. It is time to focus on pustular psoriasis. JAMA Dermatol. 2022;158(1):13–4.
31.
Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021–6.
32.
Li M, Han J, Lu Z, Li H, Zhu K, Cheng R, et al. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris. J Invest Dermatol. 2013;133(11):2637–9.
33.
Wang Y, Cheng R, Lu Z, Guo Y, Yan M, Liang J, et al. Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes. J Dermatol Sci. 2017;85(3):235–40.
34.
Berki DM, Liu L, Choon SE, David Burden A, Griffiths CEM, Navarini AA, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. J Invest Dermatol. 2015;135(12):2964–70.
35.
Zhang L, Yang H, Wang Y, Chen Y, Zhou H, Shen Z. Self-medication of psoriasis in southwestern China. Dermatology. 2014;228(4):368–74.
36.
Li X, Luo D, Qiu YY, Chen ML, Su J, Yi M. Characteristics of health seeking behaviors for patients with psoriasis in a general hospital. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016;41(6):612–8.
37.
Zhang GW, Zhou YH, Liu XS. Epidemiology and natural history of psoriasis in Chongqing area. Dermatol Venereol. 1993;15(4):56–67.
38.
Nie YF, Wang ZB, Zhang JM, Tong MQ, Yang L, Zhou SH, et al. Analysis of 226 cases of psoriasis among 100,000 natural population in Binzhou City, Shandong Province. J Binzhou Med Coll. 1986;9(1):10–4.
39.
Liu CH, Mao WH, Li JD, Wang HY. Epidemiological survey report of psoriasis in Shanghai in 1985. Dermatol Venereol. 1990;12(2):56–64.
40.
Ren T. Investigation and analysis of psoriasis in Tianjin area. Dermatol Venereol. 1992;14(4):55–7.
41.
Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–8.
42.
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360(23):2426–37.
43.
Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8.
44.
Olin A, Henckel E, Chen Y, Lakshmikanth T, Pou C, Mikes J, et al. Stereotypic immune system development in newborn children. Cell. 2018;174(5):1277–92.e14.
45.
Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.
46.
Akiyama M. Early-onset generalized pustular psoriasis is representative of autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2019;143(2):809–10.
47.
Akiyama M. Autoinflammatory keratinization diseases (AiKDs): expansion of disorders to Be included. Front Immunol. 2020;11:280.
48.
Posso-De Los Rios CJ, Pope E, Lara-Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol. 2014;31(4):430–9.
49.
National Bureau of Statistics of China. China statistical yearbook; 2017.
50.
Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645–51.
51.
Ratnarajah K, Jfri A, Litvinov IV, Netchiporouk E. Spesolimab: a novel treatment for pustular psoriasis. J Cutan Med Surg. 2020;24(2):199–200.
52.
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–40.
53.
Guo JZ, Wang WH, Zhang CL. Restrospective analysis of 251 hopitalized psoriasis patients. Chin J Dermatovenereol. 2019;33(04):420–4.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.